Sells spinal and limb-reconstruction devices, biologics and surgical navigation systems to hospitals, surgery centers and healthcare providers.
10-K for FY2025, filed Feb 24, 2026Within the Global Spine segment, we provide implantable medical devices, biologics, enabling technologies, and other regenerative solutions…View ↗
Within Enabling Technologies, we design, develop, and market a portfolio of navigation technologies including tracked surgical tools…View ↗
Global Limb Reconstruction offers products and solutions for the underserved limb reconstruction market that encompasses four pillars…View ↗
We market and sell our products principally to physicians, hospitals, ASCs, integrated health delivery systems, and other purchasing…View ↗
Global Spine is the larger business: hospitals pay for implants when used and navigation systems when installed; insurers and government payors reimburse bone-growth devices after fitting and acceptance. Distributors pay when products ship, and biologics marketing fees are earned when the tissue products ship.
10-K for FY2025, filed Feb 24, 2026The largest portion of Bone Growth Therapies revenue is derived from third-party payors. This includes commercial insurance carriers…View ↗
Biologics revenue is largely attributable to the U.S. and is mostly processed from within the Company’s Irvine facility. In addition, the…View ↗
Commercial revenue is largely related to the sale of the Company’s Spinal Implants and Global Limb Reconstruction products to hospital…View ↗
Other revenues within the Spinal Implants and Global Limb Reconstruction product categories are derived from stocking distributors, who…View ↗
Enabling technologies revenue is primarily comprised of sales of the 7D Flash Navigation Systems and related instruments to hospitals…View ↗
10-K for FY2025, filed Feb 24, 2026
FY2025 revenue by reportable segment ↗$822.3M
10-K for FY2025, filed Feb 24, 2026
$822.3M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Global Spine
Sold outright
|
84%
FY2022: 77%
|
Global Spine, FY2025
$687.7M Sources
|
Sold outright |
|
Global Limb Reconstruction
Sold outright
10-K for FY2025, filed Feb 24, 2026 |
16% |
Global Limb Reconstruction, FY2025
$134.7M Sources
|
Sold outright |
Hospitals, surgery centers, physicians and healthcare providers are reached through direct sales representatives, sales agents and distributors. Outside the U.S., stocking distributors buy products directly and resell them.
10-K for FY2025, filed Feb 24, 2026We have a broad sales network comprised of direct sales representatives, sales agents, and distributors. This established sales network…View ↗
Outside the U.S., we employ direct sales representatives in certain markets and also contract with independent stocking distributors, who…View ↗
We market and sell our products principally to physicians, hospitals, ASCs, integrated health delivery systems, and other purchasing…View ↗
No. It lost $92.2M in FY2025.
10-Q for Q3 FY2026, filed Nov 9, 2026
−$6.1MView ↗
10-Q for Q3 FY2026, filed Nov 9, 2026
Open tableView ↗
8-K, filed Apr 9, 2026
Net sales expected to range between $850 million to $860 million. The Company’s expected net sales represent implied year-over-year pro…View ↗
Growing. Revenue grew 77% in 4 years, from $464.5M in FY2021 to $822.3M in FY2025, about 15% a year.
Disc product lines
Earlier strategy emphasized expansion in cervical disc replacement, while the latest report says it plans to discontinue artificial cervical and lumbar disc lines and redirect those resources and investments.
10-K for FY2022, filed Mar 6, 2023 10-K for FY2025, filed Feb 24, 2026Continued expansion of our presence in the U.S cervical disc replacement market through surgeon training, publication of clinical evidence…View ↗
In February 2025, we announced our intent to discontinue our M6-C artificial cervical disc and M6-L artificial lumbar disc product lines…View ↗
Competes with EBI, Enovis, Bioventus, Theragen, Xstim, Alphatec Spine, Baxter, B. Braun, Brainlab, Cerapedics, Johnson & Johnson, Globus Medical, Highridge Medical, Medtronic, VB Spine, XTANT Medical, Stryker, Smith & Nephew, Paragon 28, and OrthoPediatrics
10-K for FY2025, filed Feb 24, 2026Our Bone Growth Therapies product category competes principally with similar products marketed by EBI, Enovis, Bioventus, Theragen, and…View ↗
Loading...